NVX-CoV2373 COVID-19 Vaccine (Novavax)
Kathryn Dzintars, Pharm.D., BCPS
VACCINE TYPE
VACCINE TYPE
VACCINE TYPE
- The Novavax COVID-19 vaccine (NVX-CoV2373) is an adjuvanted vaccine containing purified, full-length rS protein. The vaccine elicits an immune response to this protein, leading to protection against COVID-19.
- Primary Series: two-dose series, given 21 days apart.
- No booster dose is recommended at this time.
- The Novavax COVID-19 vaccine is available through an Emergency Use Authorization (EUA) of the Novavax COVID-19 Vaccine for individuals 12 years of age and older.
- Mandatory requirements for the administration of the Novavax COVID-19 vaccine under the EUA are as follows:
- The vaccination provider must give the individual receiving the Novavax COVID-19 vaccine or their caregiver the “Fact Sheet for Recipients and Caregivers” before receiving the Novavax COVID-19 vaccine.
- Vaccine providers must include vaccine information in the state’s or local jurisdiction’s Immunization Information System or other designated systems.
- Vaccine providers are responsible for reporting certain events to the Vaccine Adverse Events Reporting System (VAERS):
- Vaccine administration errors, whether or not associated with an adverse event
- Serious adverse events include death, life-threatening adverse events, inpatient hospitalization/prolonged hospitalization, persistent or significant incapacity, congenital anomaly/birth defects.
- Cases of multisystem inflammatory syndrome (MIS) in children and adults
- Cases of COVID-19 that result in hospitalization and death
- Vaccine providers are responsible for responding to FDA requests for information about vaccine administration errors, adverse events, cases of MIS in adults and children, and cases of COVID-19 that result in hospitalization or death following the administration of Novavax COVID-19 vaccine to recipients.
There's more to see -- the rest of this topic is available only to subscribers.
© 2000–2024 Unbound Medicine, Inc. All rights reserved